Evidence map›Paper›PMID 41188998›Full record

ArticleJournal of ovarian research2025

Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen).

Judith Hansinger, Olaf Schoffer, Vinzenz Völkel, Michael Gerken, Pauline Wimberger, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke and 8 more

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04334239 (Wirksamkeit Der Versorgung in Onkologischen Zentren), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04334239 completednot on this map

Wirksamkeit Der Versorgung in Onkologischen Zentren

TypeobservationalSponsorTechnische Universität DresdenRan2017 to 2021Enrolled670,000ConditionsColorectal Cancer, Breast Cancer, Ovarian Cancer, Cervix CancerArmsOncological certification
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Update on ovarian cancer].Pathologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Judith Hansinger *Tumor Center Regensburg, Center of Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany. judith.hansinger@klinik.uni-regensburg.de.
Olaf Schoffer *Center for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Vinzenz VölkelTumor Center Regensburg, Center of Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany.
Michael GerkenTumor Center Regensburg, Center of Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany.
Pauline WimbergerClinic and Polyclinic for Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Veronika BierbaumCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Christoph BobethCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Martin RößlerCenter for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Patrik DrögeAOK Research Institute (WIdO), Berlin, Germany.
Thomas RuhnkeAOK Research Institute (WIdO), Berlin, Germany.
Christian GünsterAOK Research Institute (WIdO), Berlin, Germany.
Kees Kleihues-van TolArbeitsgemeinschaft Deutscher Tumorzentren e.V, Berlin, Germany.
Theresa LinkClinic and Polyclinic for Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Karin KastCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology, University of Cologne, Cologne, Germany.
Thomas PapathemelisDepartment of Gynecology and Obstetrics, Clinic St. Marien Amberg, Amberg, Germany.
Olaf OrtmannDepartment of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany.
Jochen Schmitt *Center for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Monika Klinkhammer-Schalke *Tumor Center Regensburg, Center of Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the most lethal gynecologic cancer. This study explores differences in observed survival rates among ovarian cancer patients treated in certified versus non-certified hospitals in Germany.

methodsThe study used data from German statutory health insurance (SHI) funds and clinical cancer registries (CCRs), including 20,794 insured and 4,493 registry patients diagnosed with a malignant ovarian neoplasm (ICD-10-GM code C56) from 2009 to 2017. Patients were categorized based on whether they received primary treatment at hospitals certified as ovarian cancer centers by the German Cancer Society (DKG) or at non-certified hospitals. Survival analyses were conducted using Kaplan-Meier and multivariable Cox regression methods. Adjustments were performed for age, year of diagnosis, International Union Against Cancer (UICC) stage, grade, lymphatic and venous invasion, year of index treatment, distant metastasis, Elixhauser comorbidities, and hospital criteria where available in the data source used.

resultsAfter adjustment for various confounders, treatment in certified centers was associated with a lower mortality risk, corresponding to a hazard ratio (HR) of 0.883 (95% CI 0.824-0.948; p = 0.001) in the SHI data. In the CCR data a non-significant HR of 0.964 was observed (95% CI 0.867-1.071; p = 0.490). Among patients in the CCR cohort diagnosed with UICC stage I-III disease, receiving treatment at certified centers was associated with improved survival outcomes (HR 0.825, 95% CI 0.708-0.961; p = 0.014).

conclusionTreatment in DKG-certified centers is associated with better survival in ovarian cancer patients, especially in earlier stages. Certification status may be a relevant factor when choosing a treatment facility.

trial registrationClinicalTrials.gov (identifier: NCT04334239). Retrospectively registered on 6 April 2020.

Indexed as

HospitalsOvarian NeoplasmsAdultAgedAged, 80 and overFemaleGermanyHumansMiddle AgedNeoplasm StagingRegistriesRetrospective StudiesCertificationHealthcare-related dataHealth services researchOutcome qualitySpecialized treatment

Identifiers

PMID41188998
PMCPMC12587621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.